文献速递浆细胞疾病

国际分期系统第二次修订版(R2-ISS)用于多发性骨髓瘤总生存期:欧洲骨髓瘤网络(EMN)在HARMONY项目中的报告

Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project.
PubMed 文献 · J Clin Oncol · 2022-05-23

欧洲骨髓瘤网络在HARMONY项目下收集16项临床试验中10,843例初诊多发性骨髓瘤患者的个体数据,基于ISS、del(17p)、乳酸脱氢酶、t(4;14)和1q+构建并验证了加性评分系统R2-ISS,将患者分为四组,在训练集和独立验证集中均保持预后价值。

要点

  • R2-ISS将ISS-III赋值1.5分、ISS-II赋值1分、del(17p)赋值1分、高乳酸脱氢酶赋值1分、1q+赋值0.5分。
  • R2-ISS分为I(19.2%,0分)、II(30.8%,0.5-1分)、III(41.2%,1.5-2.5分)、IV(8.8%,3-5分)四组。
  • 训练集中位OS分别为未达到 vs 109.2 vs 68.5 vs 37.9个月,中位PFS分别为68 vs 45.5 vs 30.2 vs 19.9个月。

核心结论

  • R2-ISS是一种简单的预后分期系统,能更好地对中危初诊多发性骨髓瘤患者进行分层。
  • 该评分的加性特征有利于未来纳入新的预后变量。

研究设计与样本

  • 欧洲骨髓瘤网络在HARMONY项目下收集16项临床试验中10,843例初诊多发性骨髓瘤患者的个体数据。
  • 基于预测无进展生存和总生存的顶级特征开发加性评分系统,并在训练集(N=7,072)和独立验证集(N=3,771,其中1,214例有完整数据可计算R2-ISS)中进行验证。

主要发现

  • 训练集中位随访75个月时,ISS、del(17p)、乳酸脱氢酶、t(4;14)和1q+对PFS和OS影响最大,这些变量同时存在于2,226例患者中。
  • 根据OS影响赋值:ISS-III 1.5分、ISS-II 1分、del(17p) 1分、高乳酸脱氢酶1分、1q+ 0.5分。
  • 训练集四组中位OS分别为未达到 vs 109.2 vs 68.5 vs 37.9个月,中位PFS分别为68 vs 45.5 vs 30.2 vs 19.9个月。
  • 评分在独立验证集中保持预后价值。

关键数值与推荐

  • R2-ISS I组:19.2%,0分;II组:30.8%,0.5-1分;III组:41.2%,1.5-2.5分;IV组:8.8%,3-5分。
  • 训练集四组中位OS:I组未达到 vs II组109.2个月 vs III组68.5个月 vs IV组37.9个月。
  • 训练集四组中位PFS:I组68个月 vs II组45.5个月 vs III组30.2个月 vs IV组19.9个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Patients with newly diagnosed multiple myeloma (NDMM) show heterogeneous outcomes, and approximately 60% of them are at intermediate-risk according to the Revised International Staging system (R-ISS), the standard-of-care risk stratification model. Moreover, chromosome 1q gain/amplification (1q+) recently proved to be a poor prognostic factor. In this study, we revised the R-ISS by analyzing the additive value of each single risk feature, including 1q+. PATIENTS AND METHODS: The European Myeloma Network, within the HARMONY project, collected individual data from 10,843 patients with NDMM enrolled in 16 clinical trials. An additive scoring system on the basis of top features predicting progression-free survival (PFS) and overall survival (OS) was developed and validated. RESULTS: In the training set (N = 7,072), at a median follow-up of 75 months, ISS, del(17p), lactate dehydrogenase, t(4;14), and 1q+ had the highest impact on PFS and OS. These variables were all simultaneously present in 2,226 patients. A value was assigned to each risk feature according to their OS impact (ISS-III 1.5, ISS-II 1, del(17p) 1, high lactate dehydrogenase 1, and 1q+ 0.5 points). Patients were stratified into four risk groups according to the total additive score: low (Second Revision of the International Staging System [R2-ISS]-I, 19.2%, 0 points), low-intermediate (II, 30.8%, 0.5-1 points), intermediate-high (III, 41.2%, 1.5-2.5 points), high (IV, 8.8%, 3-5 points). Median OS was not reached versus 109.2 versus 68.5 versus 37.9 months, and median PFS was 68 versus 45.5 versus 30.2 versus 19.9 months, respectively. The score was validated in an independent validation set (N = 3,771, of whom 1,214 were with complete data to calculate R2-ISS) maintaining its prognostic value. CONCLUSION: The R2-ISS is a simple prognostic staging system allowing a better stratification of patients with intermediate-risk NDMM. The additive nature of this score fosters its future implementation with new prognostic variables.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. D'Agostino M, Cairns DA, Lahuerta JJ, et al. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. J Clin Oncol. 2022. PMID: 35605179. doi:10.1200/JCO.21.02614

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。